What does the research say about Anticoagulation in AF?

Q: What does the research say about Anticoagulation in AF?

The scientific consensus on Anticoagulation in AF is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims.

Electrophysiology

Anticoagulation in AF

DOACs vs warfarin, bleeding risk, and stroke prevention

Emerging pathwayAlso known as: DOAC AF, NOAC atrial fibrillation, AF anticoagulation

3,978

Clinical questions

209

Evidence-backed

100

Claims analyzed

Followers

What the evidence says about Anticoagulation in AF

Synthesized from 209 evidence-backed clinical questions linked to this topic — 83 supporting the intervention, 75 against the intervention, 10 still contested.

Where the evidence lands

209 questions

No clear lean — the placed evidence is contested

Favor benefit

40% of all

Favor harm

36% of all

Benefit10 contestedHarm

41 more (20%) still untested — not placed on the axis.

Weak For8340%

Journal clubs discussing Anticoagulation in AF

Recent sessions

VA Journal Club: Factor XI Inhibitors and Atrial Fibrillation

UCLA #bruinhearts Journal Club Section — Fri, Aug 7, 11:00 AM EDT

Sessions from public journal clubs on Synapse. RSVP to join the live discussion.

New research on Anticoagulation in AF

Prolonged Infusion of Eptifibatide as Bridge Therapy Between Bare‐Metal Stent Insertion and Cardiovascular Surgery: Case Report and Review of the Literature

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy — Pickett A — Mar 2010

Aspirin for venous thromboprophylaxis after fracture: ready for prime time?

European Heart Journal — Vergallo R — Mar 2023

Management of Hemorrhage with the Target-Specific Oral Anticoagulants

Hospital Practice — Pluym M — Aug 2014

Bleeding complications of targeted oral anticoagulants: what is the risk?

Hematology — Levine M — Nov 2014

Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect

Clinical and Applied Thrombosis/Hemostasis — Nagakari K — Mar 2016

Elite athletes and anticoagulant therapy: an intermittent dosing strategy

Hematology — Moll S — Nov 2018

Anticoagulant activity of direct factor Xa inhibitors as a tool to ensure the effectiveness and safety of drugs intake

Kardiologiia — Вавилова Т — Dec 2019

Plasma levels do not predict thrombin generation in patients taking direct oral anticoagulants

International Journal of Laboratory Hematology — Metze M — Jun 2021

Dose adjustment based on the plasma level measurement used anti-FXa chromogenic assay on the use of non-vitamin K antagonist oral anticoagulants (NOACs) improved the overall benefit of NOACs dosing in patients with atrial fibrillation

EP Europace — Suwa M — Sep 2021

Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis

Blood Coagulation & Fibrinolysis — Wu X — Jul 2022

Usual On-therapy Ranges of Drug Concentrations in Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants: A Systematic Review and Meta-analysis

Thrombosis and Haemostasis — Vries T — Nov 2024

Cost Saving Potential of an Early Detection of Atrial Fibrillation in Patients after ICD Implantation

BioMed Research International — Reinhold T — Aug 2018

Evidence brief: Anticoagulation in AF

Anticoagulation in AF (also known as DOAC AF, NOAC atrial fibrillation, AF anticoagulation). DOACs vs warfarin, bleeding risk, and stroke prevention

Synapse tracks 8 specific clinical questions in Anticoagulation in AF, each synthesized independently from its own trial evidence. They include: "Does oral anticoagulation vs placebo improve All-Cause Mortality in Atrial Fibrillation?"; "Does dabigatran vs warfarin improve outcomes in HEART-VALVE, MECHANICAL?"; "Does rivaroxaban vs apixaban improve outcomes?"; "Does oral anticoagulants vs placebo improve Intracranial Hemorrhage in Atrial Fibrillation?"; "Does warfarin vs placebo improve All-Cause Mortality in Atrial Fibrillation?".

As of 2026-09-01, the scientific consensus on Anticoagulation in AF is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/anticoagulation-in-af.

Deterministic synthesis from Synapse's enriched corpus — 129 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

Anticoagulation in AF

What the evidence says about Anticoagulation in AF

Where the evidence lands

Strength of that evidence

Actively debated